Artificial intelligence
Model the sequence, chemistry and target interactions that shape therapeutic potential.
Discovery, written in RNA
A more programmable path to RNAi medicines.
Eleven Therapeutics unites artificial intelligence, parallel functional testing, and combinatorial chemistry to create a new generation of medicinal nucleic acids.
01 / PlatformFrom hypothesis
to a functional signal.
One platform.
Many paths to precision.
Our discovery engine turns biological complexity into an integrated, experimentally grounded search space.
Parallel functional testing
Measure a broad design space directly in relevant functional assays, rather than relying on proxy signals.
Combinatorial chemistry
Advance the molecular architectures that bring performance, precision and programmability into focus.
02 / SCSI-RNAA programmable molecular architecture.
Designed to reach the targets that matter.
SCSI-RNA is a programmable molecule built to target diseases and biological targets of interest. It represents a new design space for RNA interference—one where chemical architecture and functional performance are developed together.
Sequence-addressable
Built around the biology of the selected target.
Functionally tested
Validated through parallel experimental evidence.
Chemically configurable
Refined across a wider therapeutic design space.
03 / PipelinePrograms engineered around biological opportunity.
A discovery engine made to expand the addressable.
We are building a platform capable of opening differentiated paths across diseases where precisely designed nucleic acids can create new therapeutic options.
Target
definition
Computational and biological model building.
Functional
selection
Parallel test-and-learn cycles.
Candidate
nomination
Molecular attributes aligned to development needs.
Clinical
possibility
Advancing medicines with a clearer molecular rationale.
04 / ScienceEvidence is our operating system.
A technology platform is only as good as the questions it can answer.
We use computation to widen inquiry—and functional evidence to make the decision. The goal is not more designs. It is more informative designs.
We design with biology, not around it.
By merging model-driven iteration with parallel functional testing, Eleven Therapeutics seeks to make medicinal nucleic acid discovery more legible, more predictive and more adaptable.
Start a scientific conversationPartnering & inquiry